PTGES3L-AARSD1

Across TCGA pan-cancer cohorts, PTGES3L-AARSD1 mass-spec protein differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of PTGES3L-AARSD1’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where PTGES3L-AARSD1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types PTGES3L-AARSD1 is over-expressed in tumor.

HNSC are the cancer types where PTGES3L-AARSD1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PTGES3L-AARSD1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Female	All	+0.893	.029	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 1 strongest of 1 lineages.

PTGES3L-AARSD1–HNSC

Open the HNSC breakdown →